Retrophin, LLC, a New York-based, biotechnology company focused on discovering and developing treatments for rare and life-threatening diseases, has completed its $4m Series A financing.
The round was led by MSMB Capital, with participation from several current and former senior executives at global pharmaceutical and healthcare companies.
Led by CEO Martin Shkreli, Retrophin is currently developing treatments for focal segmental glomerulosclerosis, Duchenne Muscular Dystrophy, spinal muscular atrophy, cystic fibrosis and myotubular myopathy.
The company intends to use the capital to advance a proof-of-concept study of RE-021 (a dual acting receptor antagonist of Angiotensin and Endothelin receptors) in Focal Segmental Glomerulosclerosis (FSGS) scheduled to begin enrolling patients during the second quarter of this year.
FinSMEs
07/05/2012